CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
43.36 EUR
+0.84 (+1.98%)
Overall AFX gets a fundamental rating of 4 out of 10. We evaluated AFX against 60 industry peers in the Health Care Equipment & Supplies industry. AFX has only an average score on both its financial health and profitability. AFX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AFX was profitable.
AFX had a positive operating cash flow in the past year.
AFX had positive earnings in each of the past 5 years.
In the past 5 years AFX always reported a positive cash flow from operatings.
1.2 Ratios
AFX has a better Return On Assets (4.49%) than 63.33% of its industry peers.
AFX has a Return On Equity of 7.51%. This is comparable to the rest of the industry: AFX outperforms 55.00% of its industry peers.
AFX has a Return On Invested Capital (4.74%) which is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for AFX is in line with the industry average of 8.99%.
The 3 year average ROIC (9.30%) for AFX is well above the current ROIC(4.74%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROIC | 4.74% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
1.3 Margins
With a Profit Margin value of 7.19%, AFX perfoms like the industry average, outperforming 53.33% of the companies in the same industry.
In the last couple of years the Profit Margin of AFX has declined.
AFX has a Operating Margin of 8.55%. This is comparable to the rest of the industry: AFX outperforms 46.67% of its industry peers.
AFX's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 52.43%, AFX perfoms like the industry average, outperforming 43.33% of the companies in the same industry.
AFX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% |
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
2. Health
2.1 Basic Checks
AFX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, AFX has less shares outstanding
The number of shares outstanding for AFX has been reduced compared to 5 years ago.
The debt/assets ratio for AFX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.26 indicates that AFX is not in any danger for bankruptcy at the moment.
AFX's Altman-Z score of 3.26 is fine compared to the rest of the industry. AFX outperforms 65.00% of its industry peers.
The Debt to FCF ratio of AFX is 7.17, which is on the high side as it means it would take AFX, 7.17 years of fcf income to pay off all of its debts.
AFX has a Debt to FCF ratio of 7.17. This is comparable to the rest of the industry: AFX outperforms 48.33% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that AFX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.27, AFX is in line with its industry, outperforming 55.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Altman-Z | 3.26 |
ROIC/WACC0.69
WACC6.85%
2.3 Liquidity
A Current Ratio of 2.04 indicates that AFX has no problem at all paying its short term obligations.
The Current ratio of AFX (2.04) is comparable to the rest of the industry.
A Quick Ratio of 1.17 indicates that AFX should not have too much problems paying its short term obligations.
AFX has a Quick ratio of 1.17. This is comparable to the rest of the industry: AFX outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
The Earnings Per Share has been growing slightly by 2.35% on average over the past years.
AFX shows a small growth in Revenue. In the last year, the Revenue has grown by 5.50%.
The Revenue has been growing slightly by 7.20% on average over the past years.
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
3.2 Future
Based on estimates for the next years, AFX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.55% on average per year.
Based on estimates for the next years, AFX will show a small growth in Revenue. The Revenue will grow by 6.84% on average per year.
EPS Next Y-13.79%
EPS Next 2Y1.48%
EPS Next 3Y8.03%
EPS Next 5Y13.55%
Revenue Next Year6.32%
Revenue Next 2Y5.61%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.36, AFX can be considered very expensive at the moment.
70.00% of the companies in the same industry are more expensive than AFX, based on the Price/Earnings ratio.
AFX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.45.
Based on the Price/Forward Earnings ratio of 20.95, the valuation of AFX can be described as rather expensive.
AFX's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of AFX to the average of the S&P500 Index (34.46), we can say AFX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.36 | ||
| Fwd PE | 20.95 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 70.00% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AFX is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 46.75 | ||
| EV/EBITDA | 12.75 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)10.81
EPS Next 2Y1.48%
EPS Next 3Y8.03%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.41%, AFX has a reasonable but not impressive dividend return.
AFX's Dividend Yield is a higher than the industry average which is at 2.16.
With a Dividend Yield of 1.41, AFX pays less dividend than the S&P500 average, which is at 2.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.41% |
5.2 History
On average, the dividend of AFX grows each year by 15.07%, which is quite nice.
Dividend Growth(5Y)15.07%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
AFX pays out 33.69% of its income as dividend. This is a sustainable payout ratio.
AFX's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP33.69%
EPS Next 2Y1.48%
EPS Next 3Y8.03%
FRA:AFX (11/21/2025, 7:00:00 PM)
43.36
+0.84 (+1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners22.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.88B
Revenue(TTM)2.18B
Net Income(TTM)155.89M
Analysts73.64
Price Target55.56 (28.14%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.41% |
Yearly Dividend1.11
Dividend Growth(5Y)15.07%
DP33.69%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.71%
Min EPS beat(2)-36.67%
Max EPS beat(2)13.25%
EPS beat(4)2
Avg EPS beat(4)-5.53%
Min EPS beat(4)-36.67%
Max EPS beat(4)37.18%
EPS beat(8)6
Avg EPS beat(8)8.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.29%
Min Revenue beat(2)0.82%
Max Revenue beat(2)3.76%
Revenue beat(4)3
Avg Revenue beat(4)0.58%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.25%
PT rev (3m)-15.67%
EPS NQ rev (1m)-4.88%
EPS NQ rev (3m)-4.88%
EPS NY rev (1m)0.62%
EPS NY rev (3m)-9.15%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.36 | ||
| Fwd PE | 20.95 | ||
| P/S | 1.79 | ||
| P/FCF | 46.75 | ||
| P/OCF | 19.83 | ||
| P/B | 1.87 | ||
| P/tB | 10 | ||
| EV/EBITDA | 12.75 |
EPS(TTM)1.71
EY3.94%
EPS(NY)2.07
Fwd EY4.77%
FCF(TTM)0.93
FCFY2.14%
OCF(TTM)2.19
OCFY5.04%
SpS24.26
BVpS23.21
TBVpS4.34
PEG (NY)N/A
PEG (5Y)10.81
Graham Number29.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.49% | ||
| ROE | 7.51% | ||
| ROCE | 6.52% | ||
| ROIC | 4.74% | ||
| ROICexc | 4.83% | ||
| ROICexgc | 12.2% | ||
| OM | 8.55% | ||
| PM (TTM) | 7.19% | ||
| GM | 52.43% | ||
| FCFM | 3.82% |
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
ROICexc(3y)9.4%
ROICexc(5y)9.95%
ROICexgc(3y)15.11%
ROICexgc(5y)14.88%
ROCE(3y)12.78%
ROCE(5y)13.55%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-4.98%
ROICexc growth 3Y-28.53%
ROICexc growth 5Y-15.45%
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 7.17 | ||
| Debt/EBITDA | 1.68 | ||
| Cap/Depr | 73.33% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 13.7 | ||
| Cash Conversion | 57.69% | ||
| Profit Quality | 53.21% | ||
| Current Ratio | 2.04 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 3.26 |
F-Score4
WACC6.85%
ROIC/WACC0.69
Cap/Depr(3y)128.62%
Cap/Depr(5y)113.53%
Cap/Sales(3y)5.71%
Cap/Sales(5y)4.9%
Profit Quality(3y)45.51%
Profit Quality(5y)74.23%
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
EPS Next Y-13.79%
EPS Next 2Y1.48%
EPS Next 3Y8.03%
EPS Next 5Y13.55%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
Revenue Next Year6.32%
Revenue Next 2Y5.61%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%
EBIT growth 1Y-40.66%
EBIT growth 3Y-19.39%
EBIT growth 5Y-5.98%
EBIT Next Year57.06%
EBIT Next 3Y26.22%
EBIT Next 5Y19.92%
FCF growth 1Y-30.57%
FCF growth 3Y-31.55%
FCF growth 5Y-11.27%
OCF growth 1Y-1.41%
OCF growth 3Y-11.98%
OCF growth 5Y2.4%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 4 / 10 to AFX.DE.
Can you provide the valuation status for CARL ZEISS MEDITEC AG - BR?
ChartMill assigns a valuation rating of 3 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Overvalued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 5 / 10.
What is the valuation of CARL ZEISS MEDITEC AG - BR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 25.36 and the Price/Book (PB) ratio is 1.87.
What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 5 / 10.